Since immunotherapeutic regimens only benefit from a subset of patients, in the melanoma murine model it was investigated the efficacy of the ALDH CSC-DC vaccine combined with a dual blockade of PD-1 and CTLA-4 [169]. This evidence concerns the gene CTLA4 and melanoma.